This is the first allowance the company has from the country.
Richard Hague, the CEO of PolarityTE, has also stated that it had received a patent allowance from the USPTO. Furthermore, the company is working on starting clinical trials for three of its drugs. The move would enable the company to benefit significantly in glaucoma, anti-viral, and cancer indications, which are markets worth billions. The publication detailed how the executive plans to expand the company’s reach in the natural-based drug market. Pestano believes that the publication indicates the validity of the company’s project.ĭan Cohen, Pharmadrug’s CEO, was also covered in the Wall Street Reporter. Gary Pestano, Biodesix CEO, on the other hand, announced that it had published a peer-reviewed study on its lung cancer tests. For this reason, the CMO is the right person to lead the drug towards approval, marketing, and earning revenue.
Comments CEOs have madeĪccording to the Wall Street Reporter, the CMO of Nova Mentis, Dr Marvin Hausman, the company’s latest project has the potential to become a groundbreaking therapy for Autism and other Neurological diseases.ĭr Hausman has worked in the pharmaceutical markets for years and thus has experience working with the U.S Food and Drug Administration (FDA) to ensure the approval of therapies. This news comes with the pharmaceutical industry growing past $1.3 trillion globally. Wall Street recently published comments from the company CEOs of Pharmadrug Inc (OTCMKTS: LMLLF), Biodesix Inc (NASDAQ: BDSX), Nova Mentis Life Sciences (OTCMKTS: NMLSF), and Polarityte Inc (NASDAQ: PTE).
0 kommentar(er)
